Clinical Trials and Car T

CAR-Engineered_T-Cell_Adoptive_Transfer.jpg

Car T Therapy is becoming vitally important to treating cancer. Below is an excerpt explaining Clinical Trials with Car T.

PEr Rye Brook, N.Y. (May 2, 2018) of the leukemia & lymphoma society

The latest approval of a game-changing personalized cancer therapy on Tuesday is further proof of the promise of immunotherapy, an approach that The Leukemia & LymphomaSociety (LLS) supported early on and which holds great promise for blood cancer patients, as well as for patients with other types of cancers.

The U.S. Food and Drug Administration (FDA) granted tisagenlecleucel (Kymriah®) its second approval to treat patients with diffuse large B-cell lymphoma (DLBCL) whose cancer had worsened or returned despite two or more more earlier treatments. Kymriah was approved in August 2017, by the FDA for patients with another type of blood cancer, acute lymphoblastic leukemia, who are 25 or younger. The first approval heralded the arrival of a new era in cancer treatment…continued on first article link below

TO READ THE REST OF THIS ARTICLE AND OTHER’S ON CLINICAL TRIALS & CAR T's, check out the links below!

https://www.lls.org/lls-us-hq/news/more-progress-on-lls-supported-car-t-cell-immunotherapy-a-revolutionary-approach-to-cancer-treatment

https://www.lls.org/lls-us-hq/news/fda-approves-second-lls-supported-car-t-cell-immunotherapy-a-revolutionary-approach-to-cancer-treatment

https://www.prnewswire.com/news-releases/more-progress-on-lls-supported-car-t-cell-immunotherapy-a-revolutionary-approach-to-cancer-treatment-300641607.html

http://www.lls.org/blog/accelerating-care-and-cures-for-children

https://directorsblog.nih.gov/2017/08/30/fda-approves-first-car-t-cell-therapy-for-pediatric-acute-lymphoblastic-leukemia/